'Tarlatamab's FDA approval: shaping the future of cancer therapy'.
作者信息
Alamgir Iqra, Alamgir Unsa, Alamgir Eman, Qureshi Ayaan Ahmed, Siddiqui Muhammad Osama, Jaber Mohammed Hammad, Motwani Jatin
机构信息
University Medical and Dental College, MBBS, Faisalabad.
Liaquat National Hospital and Medical College, MBBS, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2024 Sep 10;86(10):5676-5679. doi: 10.1097/MS9.0000000000002555. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
'Tarlatamab's FDA approval: shaping the future of cancer therapy'.塔勒妥单抗获美国食品药品监督管理局批准：塑造癌症治疗的未来
Ann Med Surg (Lond). 2024 Sep 10;86(10):5676-5679. doi: 10.1097/MS9.0000000000002555. eCollection 2024 Oct.
2
Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
Hum Vaccin Immunother. 2014;10(6):1428-9.
3
Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review.澳大利亚获取美国食品药品监督管理局（FDA）批准的突破性疗法指定药物：十年回顾。
J Pharm Policy Pract. 2024 Aug 21;17(1):2389120. doi: 10.1080/20523211.2024.2389120. eCollection 2024.
4
Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation.药剂师对美国食品药品监督管理局（FDA）批准标准和突破性疗法认定的知识与认知。
Pharmacy (Basel). 2022 Sep 30;10(5):126. doi: 10.3390/pharmacy10050126.
5
How drugs are developed and approved by the FDA: current process and future directions.药物如何由美国食品药品监督管理局研发和批准：当前流程与未来方向。
Am J Gastroenterol. 2014 May;109(5):620-3. doi: 10.1038/ajg.2013.407.
6
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.具有不确定治疗价值的癌症药物的批准：欧洲和美国的监管决策比较。
Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6.
7
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.英格兰对有资格获得美国食品和药物管理局加速批准的癌症药物的覆盖范围评估。
JAMA Intern Med. 2021 Apr 1;181(4):490-498. doi: 10.1001/jamainternmed.2020.8441.
9
Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.美国食品和药物管理局批准与癌症患者免疫治疗使用差异之间的关联。
JAMA Netw Open. 2022 Jun 1;5(6):e2219535. doi: 10.1001/jamanetworkopen.2022.19535.
10
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）、加拿大卫生部（Health Canada）和澳大利亚治疗用品管理局（TGA）对新型靶向抗癌药物的初始和补充适应证批准。
Invest New Drugs. 2022 Aug;40(4):798-809. doi: 10.1007/s10637-022-01227-5. Epub 2022 Apr 7.
引用本文的文献
1
ADCs and TCE in SCLC Therapy: The Beginning of a New Era?小细胞肺癌治疗中的抗体药物偶联物和肿瘤电场治疗：新时代的开端？
Curr Oncol. 2025 Apr 30;32(5):261. doi: 10.3390/curroncol32050261.
本文引用的文献
1
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.特泊替尼治疗既往治疗的小细胞肺癌患者。
N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20.
2
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.加拿大广泛期小细胞肺癌管理共识建议。
Curr Oncol. 2023 Jun 30;30(7):6289-6315. doi: 10.3390/curroncol30070465.
3
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?塔勒妥单抗：小细胞肺癌领域的新星？
J Clin Oncol. 2023 Jun 1;41(16):2877-2880. doi: 10.1200/JCO.23.00148. Epub 2023 Apr 25.
4
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.塔拉拉单抗，一种首创的 DLL3 靶向双特异性 T 细胞衔接器，用于复发性小细胞肺癌：一项开放标签、I 期研究。
J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23.
5
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.小细胞肺癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Jul;32(7):839-853. doi: 10.1016/j.annonc.2021.03.207. Epub 2021 Apr 20.
6
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.单细胞分析揭示小细胞肺癌发生治疗抵抗后肿瘤内异质性增加。
Nat Cancer. 2020 Apr;1:423-436. doi: 10.1038/s43018-019-0020-z. Epub 2020 Feb 17.
7
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.AMG 757，一种半衰期延长的、针对 DLL3 的双特异性 T 细胞衔接器，在小细胞肺癌的临床前模型中表现出高效力和高灵敏度。
Clin Cancer Res. 2021 Mar 1;27(5):1526-1537. doi: 10.1158/1078-0432.CCR-20-2845. Epub 2020 Nov 17.
8
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
9
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
10
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.免疫检查点阻断在小细胞肺癌中产生不同临床结果的潜在免疫逃逸机制。
J Hematol Oncol. 2019 Jun 28;12(1):67. doi: 10.1186/s13045-019-0753-2.
Zotero 插件